Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZP7570 MAD Trial in Healthy Subjects
NCT04612517Phase 1Completed
- Sponsor
- Zealand Pharma
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in short bowel syndrome (SBS) and obesity comparing ZP7570 with Placebo (2 arms). Primary endpoint: Incidence of treatment emergent adverse events at Day 51. Started Oct 2020; status: completed.
02
Drugs
dapiglutide
03
Conditions
short bowel syndrome (SBS)obesity
Beyond the preview
Go deeper on NCT04612517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612517.